Extended-release carbidopa/levodopa formulations mark an important step forward in Parkinson's disease treatment aimed at improving the consistency and duration of levodopa's therapeutic effect.
Drs Salima Brillman, MD, Justin Martello, MD, FAAN, and Rajesh Pahwa, MD, review the limitations of immediate-release formulations and discuss innovations in extended-release delivery.
Motor fluctuations associated with immediate-release carbidopa/levodopa often necessitate the need for more frequent dosing, which has prompted the development of novel extended-release formulations in Parkinson's disease.
Drs Sanaz Attaripour Isfahani, MD, Alberto Espay, MD, and Michael Soileau, MD, examine the challenges of immediate-release formulations and the potential of advanced delivery options.
Providing patients with more “Good On” time has become one of the main goals of Parkinson’s therapy. Drs Richard B. Dewey Jr, MD, and Rajesh Pahwa, MD, discuss the promise of extended-release delivery for achieving more cherished “Good On” time for patients with Parkinson’s.
The goal of fine-tuning levopoda to address end-of-dose “wearing off” has been a known challenge since the introducing of IR CD/LD. Drs Fiona Gupta, MD, and Stuart H. Isaacson, MD, FAAN, examine the potential of the recent development of extended-release formulations in Parkinson’s disease.